Treatment of Spondyloarthritis in Real Clinical Practice: Focus on Interleukin-17 Blockers

Objective. To analyze the administration of interleukin-17 inhibitors to patients with spondyloarthritis in the Saratov region and to assess the features of prescription and survival of therapy with secukinumab in real-life clinical practice. Materials and methods. The medical records of 158 patients, who were treated in the rheumatological department of the «Regional Clinical Hospital» of Saratov between 2020 and October 2024, to whom interleukin-17 (IL-17) inhibitors were prescribed according to the council for administering the genetically engineered and targeted therapy. At the next stage, the features of the disease course and therapy survival in patients receiving one of IL-17 inhibitors (secukinumab) were analyzed. Results. The mean duration of treatment with secukinumab at the time of analysis was 27.0 [13.5; 35.5] months. During the year of observation, 23.7% of patients were withdrawn or switched to another genetically engineered biological drug (GEBD) or targeted agent: due to primary failure in 13 (13.4%) cases, due to secondary drug failure — in 6 (6.1%) cases. Drug withdrawal/change occurred in 21.4% of patients who received secukinumab as the first GEBD and in 29.6% of non-biologic-naive patients. Conclusion. The study showed a high survival rate of the treatment with secukinumab in patients from the Saratov region, especially in biologic-naive patients. In addition, a tendency to more frequent withdrawal of this drug in patients who had previously used other genetically engineered biological drugs or targeted therapy was noted. However, patients in this group also had the high survival rate for the treatment with secukinumab.